



First Echopulse® system in Switzerland

Malakoff, December 21st, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today a commercial agreement with the Ente Ospedaliero Cantonale (EOC) located in Switzerland. This marks the first system installation in Switzerland and will allow patients with benign thyroid nodules greater access to the benefits of this non-invasive alternative to surgery.

The EOC groups all public hospitals located in Ticino, a canton located in the Italian-speaking region of Switzerland. The group is comprised of six general hospitals and 2 specialized clinics. However, a unique feature of this group's structure is the presence of centers of excellence which serve patients from the region regardless of which hospital they initially present to. The EOC is responsible for the majority of all health care delivered in Ticino.

The Echopulse system will be operated in the Division of Nuclear Medicine and Competence Centre for Thyroid Diagnosis and Treatment at Oncology Institute of Southern Switzerland in Lugano. *"It is our objective to provide a personalized diagnosis and treatment to every patient. This non-invasive alternative to surgery is what was missing from our treatment arsenal,"* says Professor Giovanella, Director of the EOC Competence Centre for Thyroid Diagnosis and Treatment and the Head of the Nuclear Medicine Department and the PET-CT Center.

"The EOC is a strategic entry point for Theraclion in Switzerland. The site will not only spread its knowledge throughout Switzerland, but also have influence on its Italian neighbors and the international nuclear medicine communities," comments David Caumartin, CEO Theraclion.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 30 people, 53 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.



Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402



Contacts:

Theraclion

David Caumartin
CEO
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com

NewCap

Financial Communications & Investors relations
Emmanuel Huynh / Valentine Brouchet
Tel.: +33 (0)1 44 71 94 94
theraclion@newcap.fr

Kalima

Press Relations
Estelle Reine-Adélaïde/ Florence Calba
Tel. : + 33 (0)1 44 90 82 54
era@kalima-rp.fr